Contusugene ladenovec

N/A

Report date: 2022/05/25 17:35:56

Base Information

Drug NameContusugene ladenovec
Drug Alias NameAd-p53RPR/INGN 201Contusugene ladenovec GenduxAdenoviral p53Ad5CMV-p53 +[7] 
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionTumor protein p53 stimulants
TargetsTumor protein p53
Therapy Area/IndicationsLi-Fraumeni SyndromeUrinary Bladder NeoplasmsProstatic Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIntrogen
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIntrogen
Active IndicationsN/A
Inactive IndicationsLi-Fraumeni SyndromeUrinary Bladder NeoplasmsProstatic Neoplasms +[9] 

Other Information

ATC CodeN/A
Related LinksN/A